|
RCC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.03110878011148E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.57330037886538E-10 |
| Normal-vs-Stage2 |
1.239810E-02 |
| Normal-vs-Stage3 |
3.95310451040132E-11 |
| Normal-vs-Stage4 |
2.39919195621496E-12 |
| Stage1-vs-Stage2 |
1.120230E-02 |
| Stage1-vs-Stage3 |
9.512000E-02 |
| Stage1-vs-Stage4 |
3.402600E-03 |
| Stage2-vs-Stage3 |
2.396200E-04 |
| Stage2-vs-Stage4 |
1.47849999998506E-06 |
| Stage3-vs-Stage4 |
1.476790E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.10462807976364E-14 |
| Normal-vs-AfricanAmerican |
3.457600E-03 |
| Normal-vs-Asian |
3.17959999995843E-06 |
| Caucasian-vs-AfricanAmerican |
2.326000E-01 |
| Caucasian-vs-Asian |
5.008400E-01 |
| AfricanAmerican-vs-Asian |
5.383400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.70520281123277E-11 |
| Normal-vs-Female |
4.53199699990137E-11 |
| Male-vs-Female |
1.277210E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.51170187479011E-11 |
| Normal-vs-Age(41-60Yrs) |
8.71440031247062E-10 |
| Normal-vs-Age(61-80Yrs) |
4.32650000270485E-08 |
| Normal-vs-Age(81-100Yrs) |
6.93549999986054E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.270200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.354400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.932750E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.295200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.207800E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.070230E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.262900E-03 |
| Classical-VS-Follicular |
2.50980347615837E-11 |
| Classical-VS-Other |
6.232400E-01 |
| Classical-VS-Normal |
2.37587727269783E-14 |
| Tall-VS-Follicular |
1.9393997519046E-10 |
| Tall-VS-Other |
4.254200E-01 |
| Tall-VS-Normal |
1.04069997064471E-09 |
| Follicular-VS-Other |
4.861700E-03 |
| Follicular-VS-Normal |
9.194100E-02 |
| Other-VS-Normal |
1.376680E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.08690000333311E-08 |
| Normal-vs-N1 |
3.87529999978931E-07 |
| N0-vs-N1 |
2.434600E-01 |
|
|
